Related Experiment Video
Updated: Feb 2, 2026

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells
Published on: May 24, 2014
LZTR1 is a regulator of RAS ubiquitination and signaling
Johannes W Bigenzahn1, Giovanna M Collu2, Felix Kartnig1
1CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria.
Abstract:
In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Knockdown of the Drosophila LZTR1 ortholog CG3711 resulted in a Ras-dependent gain-of-function phenotype. Endogenous human LZTR1 associates with the main RAS isoforms. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). We propose that LZTR1 acts as a conserved regulator of RAS ubiquitination and MAPK pathway activation. Because LZTR1 disease mutations failed to revert loss-of-function phenotypes, our findings provide a molecular rationale for LZTR1 involvement in a variety of inherited and acquired human disorders.
Insights
Inactivating the LZTR1 gene boosts MAPK pathway activity and drug resistance in leukemia. LZTR1 regulates RAS ubiquitination, impacting cell signaling and human disorders.
Area of Science:
- Molecular Biology
- Genetics
- Cell Signaling
Background:
- Chronic myeloid leukemia (CML) drug resistance is a significant clinical challenge.
- Understanding the genetic basis of drug resistance is crucial for developing new therapies.
Purpose of the Study:
- To investigate the role of Leucine Zipper-like Transcription Regulator 1 (LZTR1) in drug resistance mechanisms in CML.
- To elucidate the molecular function of LZTR1 in RAS signaling and its impact on MAPK pathway activation.
Main Methods:
- Genetic screens in CML cells to identify genes involved in drug resistance.
- Gene knockdown experiments in Drosophila and human cell lines.
- Analysis of protein ubiquitination and cellular localization.
- Investigating the association of LZTR1 with RAS isoforms.
Main Results:
- Inactivation of LZTR1 enhanced MAPK pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
- Knockdown of the Drosophila LZTR1 ortholog CG3711 caused a Ras-dependent gain-of-function phenotype.
- LZTR1 inactivation decreased KRAS ubiquitination and increased its plasma membrane localization.
- Endogenous LZTR1 was found to associate with main RAS isoforms.
Conclusions:
- LZTR1 acts as a conserved regulator of RAS ubiquitination and MAPK pathway activation.
- Dysregulation of LZTR1 contributes to drug resistance in CML.
- LZTR1's role in RAS signaling provides a molecular basis for its involvement in human disorders.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Ras Gene
Ras is a...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
GTPases and their Regulation
Large G-proteins,...

